Heart disease remains a leading killer, and current treatments can only do so much. Now, researchers are looking at a new approach: tiny particles called extracellular vesicles, engineered to deliver healing signals directly to damaged heart tissue.
A systematic review of 50 animal studies found that these engineered vesicles improved cardiac function through several mechanisms. They reduced fibrosis (scarring), calmed inflammation, promoted new blood vessel growth, and even helped heart muscle cells survive and produce energy better.
This is exciting because it suggests a way to target multiple problems at once. But it's important to be clear: all the evidence so far comes from animal studies. No human clinical trials have been reported yet, and clinical translation is not achieved.
The review provides a theoretical basis for designing these delivery systems, but we don't yet know if the benefits will hold up in people. Safety data in humans is also absent. So while the potential is real, it's still early days.
